Singer and actor Selena Gomez is facing a federal lawsuit in Delaware alleging she and other leaders of the mental‑health start‑up Wondermind Global failed to honour commitments to build and promote the business after its launch in 2021.
Allegations centre on marketing role, product delivery
Plaintiffs say they invested nearly US$1.2 million (about US$1.2M) in the company after being told Gomez — a global celebrity with a substantial social‑media following — would serve as head of marketing and take an active role in developing the enterprise. The suit alleges the start‑up did not deliver a functioning mobile application and failed to meet other basic operational obligations, including timely payment to staff and vendors.
The complaint, filed in U.S. federal court, asserts that investors were not aware of internal problems until media reporting raised concerns about the company's operations.
"Gomez purported to sign a contract obligating her to perform and then ignored it," the lawsuit states.
What investors say they were promised
The legal filing contends investors were induced by representations that the company would build a digital product to help users strengthen their "mental fitness" and that Gomez would lend her influence to market and expand the service. The plaintiffs argue those representations formed the basis of their financial commitment and that the enterprise did not develop into a legitimate or lucrative business as promised.
- Investment amount: nearly US$1.2 million.
- Company launch: 2021.
- Core complaints: failure to produce a mobile app, missed payments, and alleged breach of contractual duties.
| Item | Detail |
|---|---|
| Investor funds | Nearly US$1.2 million |
| Start‑up launch | 2021 |
Responses and wider context
A representative for Gomez did not immediately respond to requests for comment, according to reporting. The complaint frames the dispute as one of unfulfilled promises and alleged misrepresentation, centred on whether the celebrity co‑founder and company management carried out the duties described to investors.
The case highlights tensions that can arise when high‑profile figures attach their names to health‑related ventures. Investors and regulators have increasingly scrutinized the commercialisation of mental‑health tools, particularly digital platforms that combine clinical claims with brand‑driven outreach.
At this stage the matter is a civil allegation; the filing sets out investors' claims and will proceed through the U.S. court system where both sides will have opportunity to present evidence and legal arguments.
This article reports the details contained in the court filing and media coverage. It does not offer legal analysis or medical guidance.
